Genentech (DNA)
Will Shareholders Agree to Sell Genentech?
About six months ago, Swiss drugmaker Roche offered to buy out all of Genentech's remaining stock in a deal worth $44 billion. This equaled about $89 per share and represented a 9 percent premium. The board of directors evaluated this offer and about a month later, rejected the bid saying the price significantly undervalued the company's worth and growth potential. Little else has occurred since, but on Friday, Roche took the deal directly to shareholders asking to buy their equity stake for $86.50 per share. The US biotech firm advised shareholders not to take action so it can review its current position and prepare a formal response. Investors and analysts expect an announcement within a week or two. Last Friday, Genentech's stock closed at $81.50, indicating investors are complying. Having been rejected once by the company, will Roche be rejected a second time by shareholders?
http://us.mc1115.mail.yahoo.com/mc/showMessage?fid=Inbox&sort=date&order=down&startMid=0&.rand=863630971&da=0&midIndex=15&mid=1_10169187_ANkPw0MAAL3PSYeJrg0nN2ooyYs&prevMid=1_10169885_ALUPw0MAAVVJSYePggoeMQrkc5g&nextMid=1_10168655_AMcPw0MAAQo9SYeAeQ8StXCoflE&m=1_10173247_AKkPw0MAAJI7SYeo8gchUXoQxoo,1_10171928_ANkPw0MAADcISYemYw8fPXmEKy4,1_10171215_AJEPw0MAATvNSYehmgUjMVeXJH0,1_10170619_ALUPw0MAAAsCSYeXPQBBHiqFzw4,1_10169885_ALUPw0MAAVVJSYePggoeMQrkc5g,1_10169187_ANkPw0MAAL3PSYeJrg0nN2ooyYs,1_10168655_AMcPw0MAAQo9SYeAeQ8StXCoflE,1_10168118_AK8Pw0MAASzbSYd6bw01el3Luu8,1_10165098_AKMPw0MAAJTZSYdkAwkFcztQT%2Fc,1_10166808_AMcPw0MAADi4SYdoUgMDBx8Nx%2B4,1_10163494_AM0Pw0MAARjjSYdiRQMuwVNgXlE,
Relaxation
http://lifeisallaboutsmileandcry.blogspot.com/
Monday, February 2, 2009
Subscribe to:
Posts (Atom)